Synflorix
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Synflorix (GlaxoSmithKline/Japan Vaccine) is a 10-valent pneumococcal conjugate vaccine active against Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F. Synflorix is approved in the UK and registered in France, Spain, Germany, Italy, and Japan for the prevention of invasive pneumococcal disease, pneumonia, and acute otitis media in infants and children aged from six weeks up to five years.
Analyst Outlook
Synflorix’s (10-valent pneumococcal conjugate vaccine; GlaxoSmithKline/Japan Vaccine) market share will continue to decline as it
struggles to compete with Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in the EU and Japan. Synflorix has failed to
gain a recommendation for use in the five major EU markets (France, Germany, Italy, Spain, and the UK), largely due to the ease of
switching from Prevnar 7 (7-valent pneumococcal conjugate vaccine; Pfizer) to Prevnar 13, as well as its less convenient 3+1 dosing
regimen and narrower serotype coverage
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Synflorix : Pneumococcal vaccines
LIST OF TABLES
6 Table 1: Synflorix drug profile
7 Table 2: Approval history of Synflorix for pneumococcal vaccination in Japan and the five major EU markets
8 Table 3: Late-phase trials of Synflorix for pneumococcal vaccination
9 Table 4: Synflorix for pneumococcal vaccination – SWOT analysis
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Prevnar 13 
Sign up to the